Title: Xolair in Asthma Therapy: An Overview
Volume: 10
Issue: 1
Author(s): Monica Di Domenico, Angelica Bisogno, Mario Polverino, Concetta De Rosa, Vilma Ricci and Anna Capasso
Affiliation:
Keywords:
Allergy, asthma, inflammation, Ig-E, Xolair, wheezing, coughing, bronchial hyperreactivity, tobacco, Phenothiazine derivative, episodic breathlessness, carboxylic acid, modulators, episodic, pathology, atopy, bronchial hyperresponsivity, feeding, obesity, allergens, skin prick tests, intrinsic type, IgEs, cascade, allergic reaction, plasma cells, mast cells, histamine, Inhalation, pollen, Ingestion, Touch, Injection, itchy, serum, hypersensitivity, basophils, antigen, dendritic cells, T-lymphocytes, prostaglandins, leukotrienes, eosinophils, Xolair (Omalizumab), monoclonal antibody, bioavailability, cynomolgus, reticuloendothelial system (RES), endothelial cells, dose, corticosteroids, injections, anaphylaxis, sinusitis, headache, adolescent patients, Dosing, Administration, Rhinitis, multicenter trials, screening, inhaled corticosteroids, placebo, oral steroids, seasonal allergic rhinitis, atopic dermatitis, synergism, diluents, ligand, sedimentation rate, rheumatoid arthritis, embodiments, murine monoclonal antibody, skin, perennial aeroallergen
Abstract: Asthma is a chronic lung inflammatory disease affecting from 5 to 10% of the population. It generally appears with periods of crisis alternating with free periods, but inflammation is always present. Allergic asthma manifests with paroxysmal crisis of bronchospasm, hissing-like respiratory noises, dyspnea, and respiratory distress syndrome. Different studies have shown an increase of IgE serum levels in subjects suffering from allergic asthma. Xolair is a monoclonal antibody that binds the C3 domain of IgEs, inducing a conformational change of the immunoglobulin, a concealment of FcRI and FcRII receptors binding sites, thus precluding binding by IgEs and therefore stopping the release of inflammation mediators. Xolair is indicated as add-on therapy to improve asthma control in adult and adolescent patients (12 years of age and above) suffering from severe persistent allergic asthma. The aim of this review is 1) to explore the safety and tolerability of Xolair in asthma therapy and 2) to examine recent important developments focusing on treatment strategies of asthma with Xolair.
